Diamond BioFund Inc.

As of June 30, 2026, Diamond BioFund Inc. carries a market capitalization of 16.04B, placing it among publicly traded companies globally. Its enterprise value stands at 8.90B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Diamond BioFund Inc.'s next confirmed earnings release is scheduled for November 16, 2026.

As of June 30, 2026, Diamond BioFund Inc. has 853.36M shares outstanding.

As of June 30, 2026, Diamond BioFund Inc. trades at a trailing price-to-earnings ratio of 5.47.

As of June 30, 2026, Diamond BioFund Inc. maintains a current ratio of 104.29, meaning it holds 104.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.66, indicating moderate leverage, while an interest coverage ratio of -47.65 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Diamond BioFund Inc. posted a return on equity (ROE) of 26.97, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -1.43, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 26.63, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 26.77, useful for judging operating efficiency across full business cycles.

As of the close on October 22, 2026, Diamond BioFund Inc.'s stock has declined approximately 8.97% over the past 52 weeks. The 50-day moving average sits at 16.37, while the 200-day moving average is 15.98.

These figures cover the twelve months ended June 30, 2026. EBITDA reached -130.02M, while operating income came in at -156.72M.

As of June 30, 2026, Diamond BioFund Inc. holds 7.22B in cash and equivalents against 81.72M in total debt, resulting in a net debt position of -2.53B. Total book value stands at 12.31B, with working capital of 7.17B providing operational flexibility.

Diamond BioFund Inc. produced -290.78M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -237,000.00 in capital expenditures, free cash flow totaled -291.02M - equivalent to -0.34 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.81: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.06, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Diamond BioFund Inc. shareholders.

Diamond BioFund Inc.'s most recent stock split took place on August 7, 2023 with a 50:59 split ratio.